A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus

Journal of Immunological Methods

Volumn 378, Issue 1-2, 2012, Pages 11-19

  Fabbrini, Monica ^a   Sammicheli, Chiara ^a   Margarit, Immaculada ^a   Maione, Domenico ^a   Grandi, Guido ^a   Giuliani, Marzia Monica ^a   Mori, Elena ^a   Nuti, Sandra ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Fluorescent opsonophagocytosis; Group B Streptococcus; Vaccine

Indexed keywords

BACTERIUM ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; BACTERIUM COLONY; CELL LABELING; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; ENDOSOME; FLOW CYTOMETRY; FLUORESCENT OPSONOPHAGOCYTOSIS ASSAY; IMMUNOASSAY; NONHUMAN; OPSONOPHAGOCYTOSIS; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; RABBIT; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS AGALACTIAE;

ANIMALS; ANTIBODIES, BACTERIAL; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; FLOW CYTOMETRY; FLUORESCENT DYES; HL-60 CELLS; HUMANS; IMMUNOASSAY; MICE; OPSONIN PROTEINS; PHAGOCYTOSIS; RABBITS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINATION;

BACTERIA (MICROORGANISMS); HEDYOTIS SCHLECHTENDAHLIANA; MUS; STREPTOCOCCUS SP. 'GROUP B';

EID: 84859420828     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.01.011     Document Type: Article

References (34)

1. Baker C.J., Edwards M.S., Webb B.J., Kasper D.L. Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. J. Clin. Invest. 1982, 69:394.
2. Baker C.J., Paoletti L.C., Wessels M.R., Guttormsen H.K., Rench M.A., Hickman M.E., Kasper D.L. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J. Infect. Dis. 1999, 179:142.
3. Baker C.J., Paoletti L.C., Rench M.A., Guttormsen H.K., Carey V.J., Hickman M.E., Kasper D.L. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J. Infect. Dis. 2000, 182:1129.
4. Baker C.J., Rench M.A., Fernandez M., Paoletti L.C., Kasper D.L., Edwards M.S. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J. Infect. Dis. 2003, 188:66.
5. Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with groupB streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21:3468.
6. Baker C.J., Rench M.A., Paoletti L.C., Edwards M.S. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2007, 25:55.
7. Baltimore R.S., Kasper D.L., Baker C.J., Goroff D.K. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J. Immunol. 1977, 118:673.
8. Baltimore R.S., Baker C.J., Kasper D.L. Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect. Immun. 1981, 32:56.
9. Bellaire B.H., Roop R.M., Cardelli J.A. Opsonized virulent Brucella abortus replicates within nonacidic, endoplasmic reticulum-negative, LAMP-1-positive phagosomes in human monocytes. Infect. Immun. 2005, 73:3702.
10. Boyer K.M., Gadzala C.A., Burd L.I., Fisher D.E., Paton J.B., Gotoff S.P. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease, I. Epidemiologic rationale. J. Infect. Dis. 1983, 148:795.
11. Boyer K.M., Gadzala C.A., Kelly P.D., Burd L.I., Gotoff S.P. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. II. Predictive value of prenatal cultures. J. Infect. Dis. 1983, 148:802.
12. Brigtsen A.K., Kasper D.L., Baker C.J., Jennings H.J., Guttormsen H.K. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J. Infect. Dis. 2002, 185:1277.
13. Edwards M.S., Baker C.J., kKasper D.L. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J. Infect. Dis. 1979, 140:1004.
14. Ferrieri P. GBS infections in the newborn infant: diagnosis and treatment. Antibiot. Chemother. 1985, 35:211.
15. Gibbs R.S., McDuffie R.S., McNabb F., Fryer G.E., Miyoshi T., Merenstein G. Neonatal group B streptococcal sepsis during 2years of a universal screening program. Obstet. Gynecol. 1994, 84:496.
16. Gibbs R.S., Schrag S., Schuchat A. Perinatal infections due to group B streptococci. Obstet. Gynecol. 2004, 104:1062.
17. Guttormsen H.K., Liu Y., Paoletti L.C. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Hum. Vaccine 2008, 4:370.
18. Guttormsen H.K., Mascuch S.J., West J.C., Paoletti L.C. A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B Streptococcus. Hum. Vaccine 2009, 5:461.
19. Heath P.T. An update on vaccination against group B streptococcus. Expert Rev. Vaccines 2011, 10:685.
20. Hornef M.W., Wick M.J., Rhen M., Normark S. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat. Immunol. 2002, 3:1033.
21. Huynh K.K., Grinstein S. Regulation of vacuolar pH and its modulation by some microbial species. Microbiol. Mol. Biol. Rev. 2007, 71:452.
22. Kasper D.L., Paoletti L.C., Wessels M.R., Guttormsen H.K., Carey V.J., Jennings H.J., Baker C.J. Immune response to type III group B streptococcal polysaccharide- tetanus toxoid conjugate vaccine. J. Clin. Invest. 1996, 98:2308.
23. Lancaster L., Saydam M., Markey K., Ho M.M., Mawas F. Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III. Vaccine 2011, 29:3213.
24. Law M.R., Palomaki G., Alfirevic Z., Gilbert R., Heath P., McCartney C., Reid T., Schrag S. The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. J. Med. Screen. 2005, 12:60.
25. McCracken G.H. Group B streptococci: the new challenge in neonatal infections. J. Pediatr. 1973, 82:703.
26. Moore M.R., Schrag S.J., Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect. 2003, 3:201.
27. Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., Craig A.S., Schaffner W., Zansky S.M., Gershman K., Stefonek K.R., Albanese B.A., Zell E.R., Schuchat A., Schrag S.J. Active bacterial core surveillance/emerging infections program network, epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299:2056.
28. Plested J.S., Coull P.A. Opsonophagocytosis assay using flow-cytometry. Met. Mol. Med. 2003, 71:263.
29. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19:2673.
30. Rodríguez M.E., Van der Pol W.L., Van de Winkel J.G. Flow cytometry-based phagocytosis assay for sensitive detection of opsonic activity of pneumococcal capsular polysaccharide antibodies in human sera. J. Immunol. Methods 2001, 252:33.
31. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., Keyserling H.L., Carlone G.M. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 1997, 4:415.
32. Schuchat A. Neonatal group B streptococcal disease: screening and prevention. N. Engl. J. Med. 2000, 343:209.
33. Simons E.R. Measurement of phagocytosis and of the phagosomal environment in polymorphonuclear phagocytes by flow cytometry. Curr. Protoc. Cytom. 2010, Chapter 9(Unit 9.31).
34. Wessels M.R., Haft R.F., Heggen L.M., Rubens C.E. Identification of a genetic locus essential for capsule sialylation in type III group B streptococci. Infect. Immun. 1992, 60:392.